dextromethadone
Small moleculeexperimental
Esmethadone (INNTooltip International Nonproprietary Name; developmental code name REL-1017), also known as dextromethadone, is the (S)-enantiomer of methadone. It acts as an N-methyl-D-aspartate receptor (NMDAR) antagonist, among other actions. Unlike levomethadone, it has low affinity for opioid receptors and lacks significant respiratory depressant action and abuse liability. Esmethadone is under development for the treatment of major depressive disorder. As of August 2022, it is in phase 3 clinical trials for this indication. — Wikipedia
Clinical trial activity
10 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
5
Phase 4
0
Earliest trial started Dec 4, 2014 (NCT03637361)
Timeline
Indications
Mechanism of action
- Glutamate [NMDA] receptor subunit 3AINHIBITOR
GRIN3A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2- Mol. weight
- 309.4452 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEsmethadone ↗
- NCATSS95RZH8AMH ↗
- WikipediaDextromethadone ↗
Also known as
- dextromethadone
- dextromethadone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06011577 | Phase 3 | Aug 17, 2023 | Relmada Therapeutics, Inc. |
| NCT05081167 | Phase 3 | Jun 2, 2021 | Relmada Therapeutics, Inc. |
| NCT04855760 | Phase 3 | Apr 1, 2021 | Relmada Therapeutics, Inc. |
| NCT04855747 | Phase 3 | Mar 30, 2021 | Relmada Therapeutics, Inc. |
| NCT04688164 | Phase 3 | Dec 4, 2020 | Relmada Therapeutics, Inc. |
| NCT04145674 | Phase 2 | Nov 30, 2019 | Ente Ospedaliero Cantonale |
| NCT03051256 | Phase 2 | Jul 1, 2017 | INC Research, Relmada Therapeutics, Inc. |
| NCT03638869 | Phase 1 | Aug 31, 2015 | Relmada Therapeutics, Inc. |
| NCT03637361 | Phase 1 | Dec 4, 2014 | Relmada Therapeutics, Inc. |
| NCT06009003 | N/A | — | Relmada Therapeutics, Inc. |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. | For profit | 9 | 9 | 4 | 2014 |
| Ente Ospedaliero Cantonale | Academic/Hospital | 1 | 1 | 1 | 2019 |
| INC Research | For profit | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1